Enhancing CAR-T Efficacy: The Role of Anti PD-1/PD-L1 Checkpoint Inhibitors in Modern Cancer Treatment

QR Code

Enhancing CAR-T Efficacy: The Role of Anti PD-1/PD-L1 Checkpoint Inhibitors in Modern Cancer Treatment

The article "Enhancing CAR-T Efficacy: The Role of Anti PD-1/PD-L1 Checkpoint Inhibitors in Modern Cancer Treatment" provides an exhaustive study on CAR-T cell therapy and its role in cancer treatment, focusing on the problem of T-cell exhaustion and tumor immune evasion. Anti-PD-1/PD-L1 c...

Full description

Saved in:

Bibliographic Details
Main Authors:	Rishi Kant, Prashanjit Roy, Amandeep Kaur, Ranjeet Kumar
Format:	Article
Language:	English
Published:	Thieme Revinter Publicações Ltda. 2025-06-01
Series:	Journal of Coloproctology
Subjects:	Cancer immunotherapy PD-1/PD-L1 T cell exhaustion conventional chemotherapy
Online Access:	http://www.thieme-connect.de/DOI/DOI?10.1055/s-0045-1809675
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors
by: Miao Wang, et al.
Published: (2021-12-01)

Metabolism of tryptophan in non-small lung cancer patients with different effect of PD-1 / PD-L1 inhibitors immunotherapy
by: E. Yu. Zlatnik, et al.
Published: (2022-06-01)

Integrating clinical trial landscapes and bibliometric analysis: unveiling the impact of PD-1/PD-L1 inhibitors on renal cell carcinoma research and therapeutic trajectories summary
by: Yuanbin Huang, et al.
Published: (2025-07-01)

Activity of Negative Regulation of the PD-1/PD-L1/PD-L2 T-Cell Response System in Patients with Pneumonia and Inﬂuenza A (H1N1)
by: A. V. Malyarchikov, et al.
Published: (2021-08-01)

Clinical efficacy and safety of anti-PD-1/PD-L1 treatments in non-small cell lung cancer (NSCLC)
by: Tian Zeng, et al.
Published: (2019-12-01)

Visualization of PD-L1-positive and PD-1-positive immune cell contact in the breast cancer microenvironment
by: A. Yu. Kalinchuk, et al.
Published: (2024-03-01)

Spotlight on nuclear PD-L1 in ovarian cancer chemoresistance: hidden but mighty
by: Meshach Asare-Werehene, et al.
Published: (2025-07-01)

Current Advances and Future Directions for Sensitizing Gastric Cancer to Immune Checkpoint Inhibitors
by: Wenke Li, et al.
Published: (2025-07-01)

ROLE OF PD-L1 ASSESSMENT IN THE ASPECT OF MOLECULAR-GENETIC CLASSIFICATION OF COLORECTAL CANCER. CURRENT STATE OF THE PROBLEM
by: S. V. Vtorushin, et al.
Published: (2021-03-01)

The regulatory effects of PD-1/PD-L1 inhibitors on bone metabolism: opportunities and challenges in osteoporosis management
by: Jia-Wen Wang, et al.
Published: (2025-07-01)

Monitoring Pseudoprogression Using Circulating Small Extracellular Vesicles Expressing PD‐L1 in a Melanoma Patient Treated With Immune Checkpoint Inhibitors
by: Charlée Nardin, et al.
Published: (2025-06-01)

Immunotherapy of cancer tumors with inhibition of PD-1 membrane protein and its ligands interaction
by: A. V. Chetveryakov, et al.
Published: (2021-10-01)

Synthesis and Evaluation of [<sup>18</sup>F]AlF-NOTA-iPD-L1 as a Potential Theranostic Pair for [<sup>177</sup>Lu]Lu-DOTA-iPD-L1
by: Guillermina Ferro-Flores, et al.
Published: (2025-07-01)

Relationship between the expressions of PD-L1 and tumour-associated fibroblasts in gastric cancer
by: Linsong Mu, et al.
Published: (2019-12-01)

Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1
by: Mengzhen Jiang, et al.
Published: (2023-12-01)

The predictive value of total body PET/CT in high PD-L1 expression and immunotherapy in advanced non-small cell lung cancer patients
by: Huibin Jin, et al.
Published: (2025-07-01)

Combined radiation and immune checkpoint inhibitor therapy for metastatic or recurrent hepatocellular carcinoma: a real-world study of 108 patients
by: Yirui Zhai, et al.
Published: (2025-08-01)

Targeting Exosomal PD-L1 as a New Frontier in Cancer Immunotherapy
by: Laura Denisa Dragu, et al.
Published: (2025-07-01)

The DNA mismatch repair protein, MSH6 is a novel regulator of PD-L1 expression
by: Kirsten Brooksbank, et al.
Published: (2025-09-01)

Efficacy and safety of cadonilimab (PD-1/CTLA-4 bi-specific antibody) and adjuvant anti-angiogenesis therapy in treated, recurrent, or metastatic cervical cancer
by: Fang Zhou, et al.
Published: (2025-06-01)

Evaluation of the Effectiveness and Safety Profile of First-Line Immune Checkpoint Inhibitors Combined with Chemotherapy in Pulmonary Sarcomatoid Carcinoma
by: Du H, et al.
Published: (2025-06-01)

QUANTITATIVE EXPRESSION FEATURES OF PD-1 AND TIM-3 CHECKPOINT MOLECULE RECEPTORS ON CD4⁺ AND CD8⁺ T-CELLS IN BREAST CANCER OF VARYING PROGRESSION DEGREES
by: Yu. A. Shevchenko, et al.
Published: (2021-10-01)

Successful anti-PD-1 therapy in metastatic endometrial cancer with microsatellite instability: a case report
by: T. T. Andabekov, et al.
Published: (2019-07-01)

Development and Validation of a Biolayer Interferometry Method for Determination of Human Anti-PD-1 Monoclonal Antibody Concentration in Cynomolgus Serum
by: K. V. Ulyanova, et al.
Published: (2020-12-01)

PD-L1 as a Potential Target in Cancer Therapy (Review)
by: N. N. Andrusova, et al.
Published: (2021-02-01)

Modern possibilities of using immunotherapy in the treatment of cervical cancer
by: A. V. Tarasova, et al.
Published: (2021-09-01)

Polymer-assisted PD-L1 degradation and targeted photodynamic therapy synergize to suppress immunodeficient tumors
by: Changyong Guo, et al.
Published: (2025-07-01)

INFLUENCE OF ANTIBODIES AGAINST CTLA-4 AND PD-1 UPON QUANTITIES OF THEIR TARGET RECEPTORS
by: I. O. Chikileva, et al.
Published: (2019-01-01)

An investigation of the relationship between sPD-1, sPD-L1 and severe pneumonia patients admitted to ICU and its clinical significance
by: Zirong Gao, et al.
Published: (2025-06-01)

Ginseng-Derived Exosomes Attenuate Immune Evasion in NSCLC via PD-L1 Modulation
by: Zhu LJ, et al.
Published: (2025-07-01)

A Chemoinformatics Investigation of Spectral and Quantum Chemistry Patterns for Discovering New Drug Leads from Natural Products Targeting the PD-1/PD-L1 Immune Checkpoint, with a Particular Focus on Naturally Occurring Marine Products
by: Henrique Rabelo, et al.
Published: (2025-06-01)

High matrix metalloproteinase-2 expression predicts poor prognosis of colon adenocarcinoma and is associated with PD-L1 expression and lymphocyte infiltration
by: Yiyi Xiao, et al.
Published: (2025-06-01)

Characterization of a Potential Therapeutic Anti-Canine PD-1 Single Domain Antibody Produced in Yeast
by: Kartikeya Vijayasimha, et al.
Published: (2025-07-01)

Prognostic significance of PD-L1 expression and evaluation of microsatellite instability status in patients with retroperitoneal leiomyosarcomas
by: V. Е. Bugaev, et al.
Published: (2019-11-01)

MODERN POSSIBILITIES OF THERAPY WITH INHIBITORS OF CONTROL POINTS IN METASTATIC UROTHELIAL CANCER
by: R. A. Gafanov, et al.
Published: (2018-03-01)

Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors
by: Sho Yoshimoto, et al.
Published: (2023-12-01)

Distinct Roles of HHLA2 and PD-L1 in the Immune Cell and Prognosis of Hepatocellular Carcinoma
by: Wang CH, et al.
Published: (2025-07-01)

An integrative model with HLA‐DR, CD64, and PD‐1 for the diagnostic and prognostic evaluation of sepsis
by: Guosheng Chen, et al.
Published: (2024-01-01)

Common Ɣ-chain cytokine receptors as functional phenotype markers of PD-1and TIM-3-positive T cells in multiple myeloma
by: E. V. Batorov, et al.
Published: (2023-02-01)

Exosomal PD-L1 detection in cancer predictive biomarker for response to immune checkpoint blockade therapy
by: Tetsuichi Kansha, et al.
Published: (2025-07-01)